Conference Coverage (ASCO)

Combination Therapy Well Tolerated in Ovarian Cancer Patients

Published in Women's Health Weekly, June 14th, 1999

Suicide gene therapy followed by concomitant chemotherapy after debulking surgery for recurrent ovarian cancer was well tolerated and non-toxic to patients.

A. Hasenburg, representing colleagues from the Freiburg University Medical Center, Germany, and the Baylor College of Medicine, Texas, presented data from a Phase I study of adenovirus-mediated herpes simplex virus-thymidine kinase (HSV-TK) suicide gene therapy combined with topotecan chemotherapy and surgery in ovarian cancer patients with recurrent disease at the 35th Annual Meeting of the American Society of Clinical Oncology, held May 15-18, 1999, in Atlanta, Georgia (abstract "Phase I Study of Adenovirus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1999-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry